| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| CSTLCastle Biosciences, Inc. | 1.19B | 40.75 | 65.73 | 51.09% | -3.56% | -2.62% | 3.07% | 0.06 |
| MYNZMainz Biomed B.V. | 10.78M | 1.19 | -0.05 | -0.17% | -24.92% | -6.63% | 0.54 | |
| BNRBurning Rock Biotech Limited | 301.02M | 33.32 | -0.99 | -4.02% | -22.48% | -22.06% | 0.09 | |
| MDXHMDxHealth S.A. | 190.56M | 3.71 | -3.20 | 28.29% | -40.43% | -345.31% | 4.05 | |
| PSNLPersonalis, Inc. | 853.41M | 9.61 | -7.01 | 15.15% | -106.92% | -43.1% | 0.22 | |
| EXASExact Sciences Corporation | 19.44B | 102.34 | -18.31 | 10.37% | -32.01% | -39.44% | 0.38% | 1.15 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 281.39K | 493.56K | 577.35K | 529.88K | 895.48K | 893.99K |
| Revenue Growth % | - | 0.75% | 0.17% | -0.08% | 0.69% | -0% |
| Cost of Goods Sold | 342.66K | 370.48K | 399.73K | 347.73K | 385.82K | 319.11K |
| COGS % of Revenue | 1.22% | 0.75% | 0.69% | 0.66% | 0.43% | 0.36% |
| Gross Profit | -61.27K | 123.08K | 177.62K | 182.15K | 509.66K | 574.88K |
| Gross Margin % | -0.22% | 0.25% | 0.31% | 0.34% | 0.57% | 0.64% |
| Gross Profit Growth % | - | 3.01% | 0.44% | 0.03% | 1.8% | 0.13% |
| Operating Expenses | 690.21K | 796.8K | 9.56M | 26.36M | 27.15M | 19.27M |
| OpEx % of Revenue | 2.45% | 1.61% | 16.55% | 49.74% | 30.32% | 21.56% |
| Selling, General & Admin | 570.25K | 458.37K | 9.41M | 22.81M | 17.22M | 12.77M |
| SG&A % of Revenue | 2.03% | 0.93% | 16.3% | 43.05% | 19.23% | 14.29% |
| Research & Development | 250.32K | 311.85K | 466.69K | 3.66M | 9.59M | 5.84M |
| R&D % of Revenue | 0.89% | 0.63% | 0.81% | 6.91% | 10.71% | 6.53% |
| Other Operating Expenses | -130.35K | 26.57K | -320.89K | -114.05K | 342.4K | 656.34K |
| Operating Income | -921.91K | -766.09K | -9.72M | -26.44M | -26.64M | -18.7M |
| Operating Margin % | -3.28% | -1.55% | -16.84% | -49.91% | -29.75% | -20.91% |
| Operating Income Growth % | - | 0.17% | -11.69% | -1.72% | -0.01% | 0.3% |
| EBITDA | -868.87K | -613.25K | -9.65M | -25.98M | -25.61M | -17.68M |
| EBITDA Margin % | -3.09% | -1.24% | -16.72% | -49.04% | -28.6% | -19.77% |
| EBITDA Growth % | - | 0.29% | -14.74% | -1.69% | 0.01% | 0.31% |
| D&A (Non-Cash Add-back) | 53.04K | 152.84K | 69.93K | 459.43K | 1.03M | 1.02M |
| EBIT | -755.12K | -410.48K | -11.35M | -26.1M | -26.05M | -20.58M |
| Net Interest Income | -201.94K | -268.79K | -339.17K | -289.32K | -809.58K | -1.08M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 201.94K | 268.79K | 339.17K | 289.32K | 809.58K | 1.08M |
| Other Income/Expense | -35.15K | 86.82K | -1.97M | 56.7K | 348.95K | -2.96M |
| Pretax Income | -957.05K | -586.89K | -11.7M | -26.39M | -26.3M | -21.65M |
| Pretax Margin % | -3.4% | -1.19% | -20.26% | -49.8% | -29.36% | -24.22% |
| Income Tax | 0 | 0 | 377.12K | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -957.05K | -586.89K | -11.69M | -26.45M | -26.3M | -21.65M |
| Net Margin % | -3.4% | -1.19% | -20.25% | -49.92% | -29.36% | -24.22% |
| Net Income Growth % | - | 0.39% | -18.92% | -1.26% | 0.01% | 0.18% |
| Net Income (Continuing) | -957.05K | -586.89K | -11.69M | -26.39M | -26.3M | -21.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10 | -0.05 | -1.67 | -1.87 | -1.62 | -22.36 |
| EPS Growth % | - | 0.5% | -32.33% | -0.12% | 0.13% | -12.8% |
| EPS (Basic) | -0.10 | -0.05 | -1.67 | -1.87 | -1.62 | -22.36 |
| Diluted Shares Outstanding | 11.71M | 5.61M | 7.21M | 14.16M | 16.24M | 968.23K |
| Basic Shares Outstanding | 11.71M | 5.61M | 7.21M | 14.16M | 16.24M | 968.23K |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 260.01K | 186.4K | 9.61M | 18.38M | 8.98M | 7.84M |
| Cash & Short-Term Investments | 203.59K | 122.57K | 8.73M | 17.14M | 7.07M | 6.24M |
| Cash Only | 203.59K | 122.57K | 8.73M | 17.14M | 7.07M | 6.24M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 40.8K | 44.24K | 17.76K | 259.14K | 354.51K | 213.75K |
| Days Sales Outstanding | 52.92 | 32.72 | 11.23 | 178.5 | 144.5 | 87.27 |
| Inventory | 0 | 0 | 0 | 175.47K | 613.64K | 372.87K |
| Days Inventory Outstanding | - | - | - | 184.19 | 580.52 | 426.49 |
| Other Current Assets | 0 | 0 | 0 | 0 | 135.06K | 127.29K |
| Total Non-Current Assets | 455.95K | 486.87K | 431.59K | 1.86M | 6.43M | 5.39M |
| Property, Plant & Equipment | 455.95K | 486.87K | 431.59K | 1.84M | 3.03M | 2.38M |
| Fixed Asset Turnover | 0.62x | 1.01x | 1.34x | 0.29x | 0.30x | 0.38x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 3.39M | 3.02M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 23.27K | 108 | 0 |
| Total Assets | 715.96K | 673.27K | 10.04M | 20.24M | 15.41M | 13.24M |
| Asset Turnover | 0.39x | 0.73x | 0.06x | 0.03x | 0.06x | 0.07x |
| Asset Growth % | - | -0.06% | 13.91% | 1.02% | -0.24% | -0.14% |
| Total Current Liabilities | 459.71K | 701.95K | 1.35M | 4.24M | 9.24M | 5.95M |
| Accounts Payable | 200.06K | 195.41K | 832.52K | 1.33M | 2.33M | 1.25M |
| Days Payables Outstanding | 213.1 | 192.52 | 760.19 | 1.4K | 2.2K | 1.43K |
| Short-Term Debt | 173.66K | 219.02K | 193.43K | 1.04M | 4.94M | 2.13M |
| Deferred Revenue (Current) | 2.5K | 1.51K | 0 | 199.41K | 138.89K | 0 |
| Other Current Liabilities | 0 | 98.16K | -3.22K | 0 | 388.84K | 690.58K |
| Current Ratio | 0.57x | 0.27x | 7.11x | 4.33x | 0.97x | 1.32x |
| Quick Ratio | 0.57x | 0.27x | 7.11x | 4.29x | 0.91x | 1.26x |
| Cash Conversion Cycle | - | - | - | -1.04K | -1.48K | -920.79 |
| Total Non-Current Liabilities | 2.21M | 2.71M | 2.33M | 1.9M | 2.92M | 1.24M |
| Long-Term Debt | 1.79M | 2.27M | 1.94M | 943.21K | 1.03M | 0 |
| Capital Lease Obligations | 418.14K | 447.44K | 387.77K | 959.12K | 1.17M | 865.98K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 726.98K | 376.1K |
| Total Liabilities | 2.67M | 3.41M | 3.68M | 6.14M | 12.16M | 7.19M |
| Total Debt | 2.41M | 2.98M | 2.58M | 3.23M | 7.42M | 3.27M |
| Net Debt | 2.21M | 2.86M | -6.15M | -13.91M | 349.86K | -2.96M |
| Debt / Equity | - | - | 0.41x | 0.23x | 2.28x | 0.54x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -4.57x | -2.85x | -28.67x | -91.40x | -32.91x | -17.39x |
| Total Equity | -1.95M | -2.74M | 6.36M | 14.1M | 3.25M | 6.05M |
| Equity Growth % | - | -0.41% | 3.32% | 1.22% | -0.77% | 0.86% |
| Book Value per Share | -0.17 | -0.49 | 0.88 | 1.00 | 0.20 | 6.24 |
| Total Shareholders' Equity | -1.95M | -2.74M | 6.36M | 14.1M | 3.25M | 6.05M |
| Common Stock | 106.11K | 64.27K | 141.07K | 164.9K | 235.82K | 922.13K |
| Retained Earnings | -4.37M | -4.95M | -16.64M | -43.03M | -69.33M | -90.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.31M | 2.11M | 9.74M | 18.13M | 20.83M | 27.04M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -416.5K | -468.74K | -3.22M | -14.77M | -21.94M | -17.09M |
| Operating CF Margin % | -1.48% | -0.95% | -5.58% | -27.87% | -24.5% | -19.12% |
| Operating CF Growth % | - | -0.13% | -5.87% | -3.59% | -0.49% | 0.22% |
| Net Income | -957.05K | -586.89K | -11.69M | -26.39M | -26.3M | -21.65M |
| Depreciation & Amortization | 53.04K | 60.46K | 69.93K | 379.8K | 866.41K | 1.02M |
| Stock-Based Compensation | 0 | 0 | 6.43M | 9.82M | 4.01M | 1.14M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 64.48K | 107 | 2.11M | 1.85M | -450.53K | 2.36M |
| Working Capital Changes | 423.04K | 57.59K | -138.62K | -437.4K | -64.63K | 51.75K |
| Change in Receivables | 339.62K | -99.15K | 24.21K | -211.23K | 15.54K | 64.28K |
| Change in Inventory | 0 | -160.48K | -670.73M | -172.38K | -500.19K | 29.81K |
| Change in Payables | 0 | 160.48K | 670.73M | 0 | 720.24K | 84.61K |
| Cash from Investing | 0 | -9.69K | 1.2M | -658.48K | -1.9M | -198.82K |
| Capital Expenditures | 0 | -9.69K | -16.7K | -658.48K | -1.2M | -104.95K |
| CapEx % of Revenue | - | 0.02% | 0.03% | 1.24% | 1.34% | 0.12% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -700K | -126.65K |
| Cash from Financing | 424K | 396.68K | 10.61M | 23.94M | 14.23M | 16.6M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 398.81K | 0 | -107.03K | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -416.5K | -478.42K | -3.24M | -15.43M | -23.84M | -17.34M |
| FCF Margin % | -1.48% | -0.97% | -5.61% | -29.12% | -26.62% | -19.4% |
| FCF Growth % | - | -0.15% | -5.77% | -3.77% | -0.55% | 0.27% |
| FCF per Share | -0.04 | -0.09 | -0.45 | -1.09 | -1.47 | -17.91 |
| FCF Conversion (FCF/Net Income) | 0.44x | 0.80x | 0.28x | 0.56x | 0.83x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 125.54K | 0 | 198.06K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -645.93% | -258.62% | -303.2% | -465.82% |
| Return on Invested Capital (ROIC) | - | -306.19% | -4482.93% | -10104.56% | -1056.87% | -419.72% |
| Gross Margin | -21.77% | 24.94% | 30.77% | 34.38% | 56.91% | 64.31% |
| Net Margin | -340.11% | -118.91% | -2024.79% | -4992.24% | -2936.5% | -2421.8% |
| Debt / Equity | - | - | 0.41x | 0.23x | 2.28x | 0.54x |
| Interest Coverage | -4.57x | -2.85x | -28.67x | -91.40x | -32.91x | -17.39x |
| FCF Conversion | 0.44x | 0.80x | 0.28x | 0.56x | 0.83x | 0.79x |
| Revenue Growth | - | 75.4% | 16.98% | -8.22% | 69% | -0.17% |
Mainz Biomed B.V. (MYNZ) reported $1.6M in revenue for fiscal year 2024. This represents a 472% increase from $0.3M in 2019.
Mainz Biomed B.V. (MYNZ) saw revenue decline by 0.2% over the past year.
Mainz Biomed B.V. (MYNZ) reported a net loss of $40.1M for fiscal year 2024.
Mainz Biomed B.V. (MYNZ) has a return on equity (ROE) of -465.8%. Negative ROE indicates the company is unprofitable.
Mainz Biomed B.V. (MYNZ) had negative free cash flow of $27.5M in fiscal year 2024, likely due to heavy capital investments.